ProPhase Labs, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings Per Share (Tables)

Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2023

Schedule of Basic and Diluted Net Loss Per Share

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):


	For the three months ended
	March 31, 2023		March 31, 2022
Net income - basic	$	550	$	12,494
Interest on unsecured convertible promissory note	60		232
Net income - diluted	$	610	$	12,726

Weighted average shares outstanding - basic	16,748		15,486
Diluted shares- Stock Options	22		2,232
Diluted shares- Stock Warrants	1,051		222
Unsecured convertible promissory note	240		800
Weighted average shares outstanding - diluted	18,061		18,740

Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):


	For the three months ended
Anti-dilutive securities	March 31, 2023	March 31, 2022
Common stock purchase warrants	581	455
Stock Options	870	810

Anti-dilutive securities	1,451	1,265